Long‐term effects of ustekinumab in children with inflammatory bowel disease: A systematic review
Journal of Pediatric Gastroenterology and Nutrition · 2025
DOI: 10.1002/jpn3.70163 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2025. Verfasst von Breno Oliveira Marques und 7 weiteren Autor:innen. Beteiligte Einrichtung: Federal University of Bahia, Vitória da Conquista, Bahia, Brazil. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Ustekinumab. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: None.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Ustekinumab, a monoclonal antibody used in adults, is increasingly employed in children and adolescents with refractory inflammatory bowel disease (IBD). This review aimed to analyze its long‐term efficacy and safety in the pediatric population. To this end, a systematic review was registered under PROSPERO (CRD42024555896). Articles indexed in PubMed/Medline, Cochrane Library, and Web of Science up to May 30, 2024, were screened. Quality was assessed using the Newcastle–Ottawa Scale. From 563 articles, 11 observational studies were included, analyzing 444 pediatric IBD patients. Remission rates varied: 47% at Week 16, 57%–59% at Week 26, and 40%–64% at Week 52. In addition, clinical improvements included better Z ‐scores, body mass index, reduced inflammation, and healing of mucosal and perianal disease. Five studies standardized doses by weight: 260 mg (85 kg), with maintenance doses typically 90 mg every 8–12 weeks. Some patients received concomitant therapies (e.g., methotrexate, corticosteroids, and 5‐aminosalicylic acid). While adverse effects were reported, including worsening psoriasis, cutaneous and neurological reactions, infections, elevated transaminases, and lymphopenia. Severe adverse events were rare, though anaphylaxis and one death from acute diarrhea were reported. Overall, ustekinumab shows promising clinical and laboratory outcomes in pediatric IBD. However, long‐term studies are essential to solidify evidence regarding remission rates and adverse effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Federal University of Bahia, Vitória da Conquista, Bahia, Brazil.
ORCID-Profile: Breno Oliveira Marques, Ana Beatriz Ferreira Gusmão, Ana Luiza Ferreira Gusmão, Bianca Ferraz de Almeida Silva, Gabrielle Silva Sousa, Jessica Sabrina Gonçalves Fernandes, Nikolas Brayan da Silva Bragas, Natalia Oliveira E Silva
Förderung
- None
Zitieren
APA
Marques, B. O., Gusmão, A. B. F., Gusmão, A. L. F., Silva, B. F. A., Sousa, G. S., Fernandes, J. S. G., Bragas, N. B. D. S., & Silva, N. O. E. (2025). Long‐term effects of ustekinumab in children with inflammatory bowel disease: A systematic review. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70163
Vancouver
Marques BO, Gusmão ABF, Gusmão ALF, Silva BFA, Sousa GS, Fernandes JSG, et al. Long‐term effects of ustekinumab in children with inflammatory bowel disease: A systematic review. Journal of Pediatric Gastroenterology and Nutrition. 2025. doi:10.1002/jpn3.70163
BibTeX
@article{Marques2025,
author = {Marques, Breno Oliveira and Gusmão, Ana Beatriz Ferreira and Gusmão, Ana Luiza Ferreira and Silva, Bianca Ferraz de Almeida and Sousa, Gabrielle Silva and Fernandes, Jessica Sabrina Gonçalves and Bragas, Nikolas Brayan da Silva and Silva, Natalia Oliveira E},
title = {Long‐term effects of ustekinumab in children with inflammatory bowel disease: A systematic review},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2025},
doi = {10.1002/jpn3.70163}
}
EUVIMED